Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 2, 2025

5 American Companies Reshoring After Trump’s Tariffs (AAPl, GE, INTC, NVDA, WHR)

View original at finance.yahoo.com
5 American Companies Reshoring After Trump’s Tariffs (AAPl, GE, INTC, NVDA, WHR) Courtesy of United Artists Picture this scenario: A society is plagued by bandits who pilfer its citizens’ resources, funds, and livelihoods, forcing those who are able to escape to flee elsewhere…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GE has already invested $6.5 billion in the US since 2016 for manufacturing, product innovation, and plant modernization

    80% confidence

  • Over $15 trillion in US corporate investment and resuscitation of US manufacturing resulted from Trump's policies

    80% confidence

  • Nvidia's US manufacturing will create hundreds of thousands of new jobs and drive trillions of dollars in economic security over coming decades

    80% confidence

  • Manufacturing jobs aren't coming back, workers should learn to code

    80% confidence

  • Apple's US investment will create 2.9 million maintained jobs and 20,000 new hires across 24 facilities

    80% confidence

  • Whirlpool's Ohio investment will create between 450 to 600 new jobs

    80% confidence

Data points we hold from this source

Donald Trump · total corporate investment15 trillion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com